Pharmaceutical toxicology experts are integral to ensuring the safety and efficacy of new drugs throughout the development process. They assess the potential risks of pharmaceutical compounds by conducting preclinical studies, analyzing data, and interpreting toxicological findings to inform drug development decisions. Their expertise is crucial in identifying potential adverse effects and determining safe dosage levels, thereby protecting public health and ensuring regulatory compliance.
Pharmaceutical toxicology experts collaborate closely with research and development teams, regulatory agencies, and other stakeholders to provide toxicological insights during the drug design process. They play a key role in preparing regulatory submissions, such as pre-IND and IND packages, and may participate in meetings with agencies like the FDA and EMA to address safety concerns and support clinical development. Their work not only contributes to the development of safe and effective medications but also supports the pharmaceutical industry’s efforts to meet evolving regulatory requirements and market demands. Their contributions are pivotal in shaping the future of personalized medicine and targeted therapies. Additionally, pharmaceutical toxicology experts often engage in post-market surveillance to monitor the long-term safety of drugs, identifying rare or delayed adverse effects that may not have been apparent during clinical trials. They also contribute to the development of safety standards and guidelines that influence public health policies and practices.
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand